Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Graft Polymer (UK) PLC ( (GB:SVNS) ) has issued an announcement.
Solvonis Therapeutics plc has secured an exclusive collaboration with Professor David Nutt, a leading authority in neuropsychopharmacology, to enhance its CNS drug discovery and development efforts. Professor Nutt will serve as Interim Chair of the newly established Scientific Advisory Committee, providing strategic oversight and guidance. This collaboration strengthens Solvonis’ position in the CNS field, aiming to translate cutting-edge neuroscience into innovative therapies. Additionally, Solvonis has issued new equity to settle outstanding liabilities, with new shares expected to be admitted to trading on the London Stock Exchange.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange, Solvonis is advancing a pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions. Its lead programs address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with SVN-001 in Phase 3 trials in Europe and the UK for severe AUD.
Average Trading Volume: 102,696,143
Technical Sentiment Signal: Hold
Current Market Cap: £18.47M
See more data about SVNS stock on TipRanks’ Stock Analysis page.